Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups

Abstract

Glycopyrronium (GLY) and tiotropium (TIO) are inhaled LAMAs recommended for COPD patients in all GOLD groups (A,B,CD BD ≥7/ 2 and lung function (FEV 1 ; 50% predicted normal) not considering baseline exacerbation risk. Efficacy of GLY and TIO was measured by mean change from baseline at 12 weeks for trough FEV 1 (tFEV1), health status (SGRQ score) and dyspnea (TDI score). Out of 2599 patients (GLY=1628; TIO=971),30.6% and 26.7% were in the low-symptom groups AC 29.7% and 13.1% patients were in the high-symptom groups BD there was no significant difference between GLY and TIO. In conclusion, GLY improved lung function, dyspnea and health status in COPD patients in all GOLD groups, similar to TIO. GOLD 2015 Ozalevli et al 2006 J Eval Clin Pract 12 ; 532–538.